Skip to content

Study · Systematic review · 2024

5 results

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.

Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L and 16 more

Show all authors

Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S

Lancet (London, England)1 Apr 2024Cited by 119 (Europe PMC)

PMID38582569 (opens in a new tab)DOI10.1016/s0140-6736(24)00351-9 (opens in a new tab)PepBankPUB-38582569
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight and obesity, semaglutide raised the likelihood of 5% or more weight loss versus lifestyle modification (OR 9.82, 95% CI 7.09 to 13.61) in a post-hoc network meta-analysis.

    In plain wordsIn adults with overweight or obesity, semaglutide made 5% weight loss much more likely than lifestyle change alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of 5% or more
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR for weight loss of 5% or more
    9.82
    semaglutide vs lifestyle modification

    Source sentences

    Summary
    In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihood of weight loss of 5% or more (OR 9·82, 95% CI 7·09 to 13·61) and percentage bodyweight change (MD -11·40, 95%…
    2 context sentences
    Summary · context
    All drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification.
    Summary · context
    This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with overweight and obesity, semaglutide lowered percentage bodyweight by a mean difference of -11.40 (95% CI -12.51 to -10.29) versus lifestyle modification.

    In plain wordsIn adults with overweight or obesity, semaglutide lowered body weight more than lifestyle change alone.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage bodyweight change
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MD percentage bodyweight change
    −11.4%
    semaglutide vs lifestyle modification

    Source sentences

    Summary
    In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihood of weight loss of 5% or more (OR 9·82, 95% CI 7·09 to 13·61) and percentage bodyweight change (MD -11·40, 95%…
    2 context sentences
    Summary · context
    All drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification.
    Summary · context
    This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity.
  3. 03HumanSystematic reviewSafety outcome

    In adults with overweight and obesity, semaglutide showed a similar risk of adverse events as other weight-lowering drugs.

    In plain wordsIn adults with overweight or obesity, semaglutide had a similar risk of side effects as other weight-loss drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse event risk
    Study

    n: not reported in source

    Comparator
    Other weight-lowering drugs
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihood of weight loss of 5% or more (OR 9·82, 95% CI 7·09 to 13·61) and percentage bodyweight change (MD -11·40, 95%…
    1 context sentence
    Summary · context
    This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight and obesity, pooled GLP-1 receptor agonists raised the likelihood of 5% or more weight reduction (OR 6.33) and lowered bodyweight (MD -5.79) versus lifestyle modification.

    In plain wordsIn adults with overweight or obesity, GLP-1 drugs as a class lowered weight more than lifestyle change alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss with pooled GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    OR for weight reduction of 5% or more
    6.33
    GLP-1 receptor agonists
    MD percentage bodyweight change
    −5.79%
    GLP-1 receptor agonists

    Source sentences

    Summary
    followed by GLP-1 receptor agonists (OR 6·33, 95% CI 5·00 to 8·00; MD -5·79, 95% CI -6·34 to -5·25).
    2 context sentences
    Summary · context
    All drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification.
    Summary · context
    This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 05HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with overweight and obesity, pooled GLP-1 receptor agonists were linked to more adverse events leading to drug discontinuation (OR 2.22) versus lifestyle modification.

    In plain wordsIn adults with overweight or obesity, GLP-1 drugs as a class led to more stopped treatment from side effects than lifestyle change alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiscontinuation for adverse events with pooled GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Adverse events · Whole body

    Measurements

    OR for discontinuation due to adverse events
    2.22
    GLP-1 receptor agonists

    Source sentences

    Summary
    Naltrexone-bupropion (OR 2·69, 95% CI 2·10 to 3·44), phentermine-topiramate (2·40, 1·68 to 3·44), GLP-1 receptor agonists (2·22, 1·74 to 2·84), and orlistat (1·71, 1·42 to 2·05) were associated with increased adverse events leading to drug discontinuation.
    2 context sentences
    Summary · context
    All drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification.
    Summary · context
    This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.